JPRN-jRCT1041220027
Recruiting
Phase 2
Phase II study of FOLFIRINOX for the patients with resectable or borderline resectable pancreatic adenocarcinoma
Yamashita Tatsuya0 sites50 target enrollmentJune 4, 2022
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Pancreatic cancer
- Sponsor
- Yamashita Tatsuya
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Pathologically diagnosed as pancreatic adenocarcinoma or adenosquamous carcinoma; diagnosed as resectable or borderline resectable (BR\-PV) (cohort1\) or borderline resectable (BR\-A); 20\-80 years or older; ECOG Performance status 0 or 1; preservation of major organ function; written informed consent
Exclusion Criteria
- •double cancer; severe infection; refractory ascites or pleural effusion; pregnant or lactating women, or women of childbearing potential; metastases to central nervous system; mental disorder; severe complication; patients who investigator regards as inappropriate for candidate
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A phase II study of FOLFIRINOX in patients with advanced biliary tract cancerBiliary tract cancerJPRN-UMIN000020801Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo35
Not yet recruiting
Phase 2
Converison therapy of FOLFIRINOX in patients with unresectable locally advanced pancreatic cancer: A phase IInresectable locally advanced pancreatic cancerJPRN-UMIN000014039Yokohama City University50
Completed
Not Applicable
Feasibility and efficacy of FOLFIRINOX therapy in patients with borderline resectable pancreatic cancer in the neoadjvant setting.Borderline resectable pancreatic cancerJPRN-UMIN000034509Department of Hepatobiliary Pancreatic Surgery, Saitama Medical Center, Saitama Medical University30
Active, not recruiting
Phase 1
_RAS and B-RAF wild-type metastatic colorectal cancer.MedDRA version: 19.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-001490-33-FRICANCER209
Completed
Not Applicable
Observational study of FOLFIRINOX therapy for unresectable and recurrence pancreatic cancerunresectable and recurrence pancreatic cancerJPRN-UMIN000014658Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)329